Target Name: RET
NCBI ID: G5979
Review Report on RET Target / Biomarker Content of Review Report on RET Target / Biomarker
RET
Other Name(s): Soluble RET kinase fragment | Ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease) | cadherin-related family member 16 | Proto-oncogene tyrosine-protein kinase receptor Ret (isoform a) | Ret9 | RET51 | RET variant 2 | Ret proto-oncogene, transcript variant 2 | proto-oncogene c-Ret | RET_HUMAN | cadherin family member 12 | RET-ELE1 | Receptor tyrosine kinase | Ret proto-oncogene | CDHR16 | ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease) | MEN2A | Ret51 | Proto-oncogene c-Ret | hydroxyaryl-protein kinase | MEN2B | Cadherin-related family member 16 | ret proto-oncogene | C-ret | Cadherin family member 12 | Hydroxyaryl-protein kinase | MTC1 | RET transforming sequence | Extracellular cell-membrane anchored RET cadherin 120 kDa fragment | HSCR1 | PTC | Proto-oncogene tyrosine-protein kinase receptor Ret | RET receptor tyrosine kinase | rearranged during transfection | CDHF12 | Proto-oncogene tyrosine-protein kinase receptor Ret precursor

RET as A Drug Target for RB: Potential and Side Effects

Retinoblastoma (RB) is a type of ocular cancer that is characterized by the rapid and uncontrolled growth of a single cell that leads to the formation of a tumor. Despite advances in treatment options, the survival rate for RB remains high, with a five-year survival rate of approximately 80%.

One of the main challenges in the treatment of RB is the development of resistance to therapy, which can lead to a relapse of the disease. To address this issue, researchers have been investigating the potential of targeting the Retinoblastoma gene (RET) to treat RB.

RET is a gene that has been identified as a potential drug target for RB. It is a transmembrane protein that is involved in a variety of cellular processes, including cell signaling, gene expression, and cell survival. Several studies have suggested that targeting RET may be an effective way to treat RB.

One of the reasons why RET is thought to be a potential drug target for RB is its involvement in the development of resistance to therapy. Studies have shown that RET is involved in the development of resistance to chemotherapy in RB cells. By targeting RET, researchers hope to reduce the development of resistance and improve the effectiveness of chemotherapy.

Another potential mechanism by which RET may be involved in the development of resistance to RB is its role in cell survival. Several studies have shown that RET is involved in the survival and proliferation of RB cells. By targeting RET, researchers hope to reduce the ability of RB cells to survive and grow, leading to a reduction in the formation of new tumors.

In addition to its potential role in the development of resistance to RB, RET is also thought to be a potential drug target for RB due to its involvement in the development of neurodegeneration. Studies have shown that RET is involved in the development of neurodegeneration in RB, which can lead to the death of the patient. By targeting RET, researchers hope to reduce the neurodegeneration and improve the overall quality of life for RB patients.

Despite the potential benefits of targeting RET, there are also concerns about the potential side effects of this approach. Studies have shown that targeting RET can lead to a variety of side effects, including skin rash, fatigue, and anemia. Additionally, there is a risk of targeting RET by mistake, which could have serious consequences for patients.

In conclusion, RET is a gene that has been identified as a potential drug target for RB. Its involvement in the development of resistance to therapy and neurodegeneration makes it an attractive target for researchers to investigate further. While there are concerns about the potential side effects of targeting RET, the potential benefits are too great to ignore. Further studies are needed to determine the effectiveness of targeting RET as a drug target for RB.

Protein Name: Ret Proto-oncogene

Functions: Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways (PubMed:28846097, PubMed:28953886, PubMed:28846099). Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL (PubMed:28846099)

The "RET Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RET comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

Retinoid acid receptor | Retinoid RXR receptor | Retinol dehydrogenase | RETN | RETNLB | RETREG1 | RETREG2 | RETREG3 | RETSAT | REV1 | REV3L | Reverse transcriptase (Telomerase) | REX1BD | REXO1 | REXO1L1P | REXO1L2P | REXO1L6P | REXO1L8P | REXO2 | REXO4 | REXO5 | RFC1 | RFC2 | RFC3 | RFC4 | RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP | RGS8 | RGS9 | RGS9BP